NRM on Vascular Perfusion in Healthy Adults
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Nicotinamide Riboside Malate, Placebo.
- Who it may be relevant to
- Registry conditions: Vascular Stiffness. Basic parameters: 35 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Effect of Oral Nicotinamide Riboside on Systemic Vascular Perfusion in Healthy Adults: A Critical Foundation of Cerebrovascular Health, Cardiovascular Health, and Healthy Aging
Overview
The purpose of this study is to better understand the effects of nicotinamide riboside supplement in overall cardiovascular health in healthy adults.
Detailed description
This study is a randomized, double-blind, placebo-controlled, parallel-dose clinical trial. Participants will be randomly assigned to one of three groups. Study measurements will be completed at three timepoints and intervention taken daily throughout the subject's 12 weeks of participation.
Interventions
- Dietary supplement Nicotinamide Riboside Malate
Active supplement. - Other Placebo
Placebo
Primary outcome measures
- Number of Participants with Reduced Endothelial Stiffness [Time frame: Baseline to End of study at 12 weeks]
Eligibility criteria
Inclusion criteria
- >= 35 and <=70
- Provides consent to participate in the study
- Not pregnant at time of consent
- Understands and agrees to follow all study procedures and limitations
- Have no contraindicating comorbid health condition as determined by the clinical investigators
Exclusion criteria
- Pregnant, nursing, or trying to conceive
- BMI Restrictions: <35
- Allergy or sensitivity to study agent ingredients
- Hypertension treated with medication
- Use of natural health products containing nicotinamide riboside, quercetin, trans-resveratrol, or betaine anhydrous within 7 days prior to randomization and during the course of the study.
- Surgery planned during the course of the trial
- History or past diagnosis of chronic diseases, unstable medical conditions, blood/bleeding disorders or stroke
- History or current diagnosis of cancer (except for successfully treated basal cell carcinoma diagnosed less than 5 years prior to screening or cancer in full remission more than 5 years after diagnosis.
- Abnormal blood chemistries for renal or liver function (defined as 1 standard deviation outside of the normal range), alcohol dependence, uncontrolled thyroid disease, severe obesity (body mass index >40 kg m-2), or weight stable for at least 3 months prior to enrolling in the study (defined as >2 kg change in body mass).
- An unstable medical or mental health condition as determined by the physician investigator.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Prevention
Study locations
United States · 1 center
- Mayo Clinic in Rochester — Rochester
Identifiers
NCT: NCT06345443 · 23-005288